Altimmune, Inc.

Analysis for Ticker: ALT

Altimmune Inc is a business focused on developing peptide-based therapies for obesity and metabolic dysfunction-associated steatohepatitis but generates 0$ from selling any medical products. The shocking reality is that the company operates as a specialized machine designed to burn cash and print new shares just to keep its doors open. By 12/2024, it had lost 95$ million and built up an accumulated deficit of over 649$ million. The math is a disaster because the business survives by constantly selling new pieces of itself, making the pieces that investors already own worth less over time. It is like owning a slice of a pizza where the chef keeps adding more slices to the same pie for new customers, which makes your slice smaller and smaller every single day.